USANA Health Sciences, Inc.
Description
USANA Health Sciences, Inc. develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products. It also provides Celavive, a skin care regimen for various skin care types and ethnicities; and other products for prenatal, infant, and young child age groups. In addition, the company offers materials and online tools to assist associates in building their businesses, as well as in marketing products. It offers its products through retail stores and online. The company has a research collaboration agreement with Beijing University of Chinese Medicine; and National Sports Training Bureau. USANA Health Sciences, Inc. was founded in 1992 and is headquartered in Salt Lake City, Utah.
About
CEO
Mr. Jim Brown
Employees
1,800
Instrument type
Common Stock
Sector
Consumer Defensive
Industry
Packaged Foods
MIC code
XNYS
Address
3838 West Parkway Boulevard, Salt Lake City, UT 84120, United States
×
![Enlarged Chart]()
Oscillators
No data available
Summary
No data available
Moving Averages
No data available
Earnings
| Date | Estimate EPS | Actual EPS | Difference | % Surprise |
|---|---|---|---|---|
| Oct 20, 2025 | — | — | — | — |
| Jul 21, 2025 | — | — | — | — |
| Apr 28, 2025 | — | — | — | — |
| Feb 26, 2025 | 0.49 | — | — | — |
| Feb 4, 2025 | 0.49 | — | — | — |
Earnings estimate
|
Next Quarter
(Mar 2025)
|
Next Year
(Dec 2025)
|
|||
|---|---|---|---|---|
| Number of analysts | — | 2 | — | 2 |
| Average estimate | — | 0.87 | — | 2.97 |
| Low estimate | — | 0.84 | — | 2.85 |
| High estimate | — | 0.90 | — | 3.09 |
| Last year EPS | — | 0.86 | — | 2.45 |
[stock_revenue_estimate]
Growth estimates
Current qtr
-43.680%
Next qtr. (Mar 2025)
1.160%
Current year
-25.760%
Next year (Dec 2025)
21.220%
Next 5 years (per annum)
—
Past 5 years (per annum)
—
Income statement
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Fiscal date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total reported revenue | 921.01M | 998.60M | 1.19B | 1.13B | 1.06B |
| Cost of revenue | 176.69M | 193.89M | 217.90M | 209.11M | 187.50M |
| Gross profit | 744.32M | 804.71M | 968.57M | 925.53M | 873.40M |
| Operating expense | |||||
| Research & development | — | — | — | — | — |
| Selling general and admin | 256.99M | 262.30M | 279.11M | 261.19M | 267.73M |
| Other operating expenses | 394.26M | 434.79M | 519.27M | 487.86M | 459.48M |
| Operating income | 93.07M | 107.61M | 170.19M | 176.49M | 146.19M |
| Non operating interest income | |||||
| Income | 9.64M | 3.79M | 2.52M | 2.54M | 4.71M |
| Expense | 262,000 | 192,000 | 57,000 | 507,000 | 66,000 |
| Other income expense | 7,000 | -2.59M | -2.01M | -571,000 | -335,000 |
| Pretax income | 102.45M | 108.62M | 170.64M | 177.95M | 150.50M |
| Tax provision | 38.67M | 39.27M | 54.14M | 53.28M | 49.97M |
| Net income | 63.79M | 69.35M | 116.51M | 124.66M | 100.53M |
| Basic EPS | 3.33 | 3.61 | 5.99 | 5.93 | 4.64 |
| Diluted EPS | 3.30 | 3.59 | 5.73 | 5.86 | 4.41 |
| Basic average shares | 19.13M | 19.21M | 19.39M | 21.04M | 21.66M |
| Diluted average shares | 19.13M | 19.21M | 19.39M | 21.04M | 21.66M |
| EBITDA | 123.11M | 130.22M | 192.89M | 200.96M | 173.57M |
| Net income from continuing op. | 63.79M | 69.35M | 116.51M | 124.66M | 100.53M |
| Minority interests | — | — | — | — | — |
| Preferred stock dividends | — | — | — | — | — |
Balance sheet
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Fiscal date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 632.76M | 596.55M | 577.74M | 640.89M | 516.93M |
| Current assets | |||||
| Cash | — | — | — | — | — |
| Cash equivalents | — | — | — | — | — |
| Cash and cash equivalents | 330.42M | 288.42M | 239.83M | 311.92M | 234.83M |
| Other short term investments | — | — | — | — | — |
| Accounts receivable | — | — | — | — | — |
| Other receivables | 6.17M | 5.18M | 5.58M | 6.25M | 6.72M |
| Inventory | 61.45M | 67.09M | 98.32M | 90.22M | 68.91M |
| Prepaid assets | 11.39M | 11.38M | 13.85M | 8.68M | 10.16M |
| Restricted cash | — | — | — | — | — |
| Assets held for sale | — | — | — | — | — |
| Hedging assets | — | — | — | — | — |
| Other current assets | 6.10M | 7.12M | 3.68M | 4.97M | 4.95M |
| Non current assets | |||||
| Properties | 54.50M | 50.68M | 47.55M | 37.20M | 33.18M |
| Land and improvements | 9.98M | 9.99M | 10.37M | 10.47M | 9.92M |
| Machinery furniture equipment | 62.32M | 63.31M | 63.92M | 63.19M | 60.51M |
| Construction in progress | 9.81M | 6.08M | 5.50M | 11.07M | 11.49M |
| Leases | 14.34M | 14.39M | 15.21M | 15.24M | 13.40M |
| Accumulated depreciation | -128.94M | -124.75M | -121.59M | -116.39M | -104.52M |
| Goodwill | 64.12M | 67.17M | 65.78M | 65.53M | 63.11M |
| Investment properties | — | — | — | — | — |
| Financial assets | — | — | — | — | — |
| Intangible assets | 29.92M | 32.43M | 30.44M | 30.80M | 29.84M |
| Investments and advances | — | — | — | — | — |
| Other non current assets | 68.18M | 64.59M | 62.73M | 66.99M | 45.95M |
| Total liabilities | 135.56M | 162.08M | 182.62M | 199.24M | 165.22M |
| Current liabilities | |||||
| Accounts payable | 10.07M | 11.05M | 13.51M | 18.20M | 12.53M |
| Accrued expenses | — | — | — | — | — |
| Short term debt | 8.06M | 6.89M | 7.08M | 8.62M | 8.32M |
| Deferred revenue | 13.91M | 20.88M | 19.64M | 15.95M | 13.85M |
| Tax payable | 12.53M | 16.21M | 16.52M | 20.27M | 16.53M |
| Pensions | 16.20M | 17.33M | 32.37M | 32.19M | 26.15M |
| Other current liabilities | 58.08M | 71.48M | 71.68M | 72.86M | 58.71M |
| Non current liabilities | |||||
| Long term debt | — | — | — | — | — |
| Provision for risks and charges | — | — | — | — | — |
| Deferred liabilities | 4.55M | 4.07M | 7.50M | 12.01M | 10.28M |
| Derivative product liabilities | — | — | — | — | — |
| Other non current liabilities | 12.16M | 14.17M | 14.33M | 19.16M | 18.84M |
| Shareholders equity | |||||
| Common stock | 19,000 | 19,000 | 19,000 | 21,000 | 22,000 |
| Retained earnings | 445.22M | 391.64M | 344.64M | 382.79M | 306.15M |
| Other shareholders equity | -13.70M | -12.79M | 458,000 | -3.63M | -13.90M |
| Total shareholders equity | 497.20M | 434.47M | 395.12M | 441.65M | 351.71M |
| Additional paid in capital | 65.66M | 55.60M | 50.01M | 62.46M | 59.45M |
| Treasury stock | — | — | — | — | — |
| Minority interest | — | — | — | — | — |
Cash flow statement
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | |||||||||||||||||||||||||||||
| Net Income | 63.79M | 69.35M | 116.51M | 124.66M | 100.53M | 126.22M | 62.54M | 100.04M | 94.67M | 76.64M | 79.02M | 66.43M | 50.75M | 45.65M | 33.56M | 29.95M | 45.32M | 41.27M | 38.99M | 30.78M | 20.82M | 8.50M | 2.20M | 2.87M | 5.90M | 9.50M | 6.60M | 5.00M | 2.30M |
| Depreciation | 20.40M | 21.41M | 22.19M | 22.51M | 23.01M | 16.84M | 16.11M | 13.48M | 9.98M | 8.81M | 9.04M | 8.83M | 8.47M | 7.92M | 7.07M | 6.70M | 5.33M | 5.56M | 5.90M | 4.84M | 3.88M | 4.14M | 4.12M | 4.19M | 4.49M | 3.38M | 2.20M | 800,000 | 300,000 |
| Deferred Taxes | -2.75M | -7.18M | -2.97M | -2.42M | -3.64M | 699,000 | 19.31M | -3.70M | -2.57M | -1.04M | 814,000 | 4.11M | -1.60M | 3.19M | -2.30M | -2.44M | -1.57M | -1.30M | -631,000 | -29,000 | -170,000 | -1.06M | 962,000 | 600,000 | -800,000 | -200,000 | -200,000 | -100,000 | -100,000 |
| Stock-Based Compensation | 14.60M | 13.33M | 14.30M | 14.39M | 15.54M | 14.96M | 15.48M | 16.54M | 11.08M | 9.81M | 7.62M | 10.21M | 10.55M | 10.41M | 8.93M | 7.69M | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Other Non-Cash Items | — | — | — | — | — | — | — | — | — | — | — | 80,000 | 50.75M | 1.28M | 824,000 | 1.00M | 4.95M | 2.27M | 1.83M | 1.73M | — | — | — | -441,000 | 110,000 | 26,000 | -100,000 | 100,000 | — |
| Accounts Receivable | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 1.35M | -1.09M | -600,000 | -500,000 | 200,000 | 100,000 | — |
| Accounts Payable | -428,000 | -2.66M | -4.57M | 6.08M | 1.84M | -1.72M | 3.04M | -1.34M | 2.48M | -1.34M | 2.79M | -985,000 | 1.50M | -1.98M | -1.14M | 686,000 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Other Assets & Liabilities | -27.68M | 6.73M | -26.16M | -328,000 | -17.81M | -4.40M | -464,000 | 21.50M | -2.13M | 30.89M | 8.47M | 13.95M | -3.97M | 21.97M | -16.00M | 10.12M | 8.83M | 11.62M | 3.64M | 3.53M | 9.65M | 3.96M | 1.29M | -2.08M | 900,000 | -3.70M | -500,000 | -5.10M | 600,000 |
| Operating Cash Flow | 67.92M | 100.98M | 119.30M | 164.89M | 119.46M | 152.60M | 116.01M | 146.52M | 113.51M | 123.76M | 107.77M | 102.63M | 116.46M | 88.43M | 30.94M | 53.70M | 62.86M | 59.41M | 49.74M | 40.85M | 34.18M | 15.54M | 9.92M | 4.04M | 10.00M | 8.50M | 8.20M | 800,000 | 3.10M |
| Investing Activities | |||||||||||||||||||||||||||||
| Capital Expenditures | -14.48M | -10.39M | -12.75M | -15.09M | -16.55M | -11.05M | -13.20M | -32.69M | -23.54M | -20.41M | -8.00M | -8.28M | -10.61M | -4.16M | -3.29M | -15.91M | -25.47M | -11.02M | -4.29M | -6.92M | -4.52M | -2.92M | -6.55M | -2.49M | -4.90M | -11.20M | -4.20M | -7.70M | -3.90M |
| Net Intangibles | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Net Acquisitions | — | -6.53M | — | — | — | — | — | — | — | — | — | — | — | -42.69M | — | — | — | — | -1.41M | -2.14M | -5.34M | — | — | — | — | — | — | — | — |
| Purchase of Investments | -1.27M | — | -1.56M | -21.09M | -1.66M | -86.40M | — | — | — | -3.87M | -8.64M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Sale of Investments | 3.78M | 4.56M | — | 1.94M | 65.48M | 23.60M | — | — | — | 12.51M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Investing Cash Flow | -11.98M | -12.37M | -14.19M | -33.96M | 47.49M | -69.00M | -12.90M | -31.88M | -25.12M | -16.27M | -21.59M | -8.28M | -10.61M | -46.85M | -3.20M | -15.21M | -26.01M | -11.68M | -5.70M | -9.06M | -9.86M | -2.92M | -6.55M | -2.49M | -4.90M | -11.70M | -4.20M | -7.80M | -3.80M |
| Financing Activities | |||||||||||||||||||||||||||||
| Long-Term Debt Issuance | — | — | — | — | — | — | — | — | — | — | — | — | — | 31.15M | 57.02M | 85.02M | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Long-Term Debt Payments | -750,000 | -11.00M | — | -60.00M | -5.00M | — | -3.50M | -73.70M | — | -30.00M | — | -1.85M | — | -38.15M | -85.01M | -78.03M | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Other Financing Charges | -3.43M | -4.71M | -3.58M | -2.41M | -2.05M | 98,000 | -316,000 | -250,000 | 12.02M | 14.83M | 7.47M | 3.44M | 48,000 | 2.45M | 11,000 | 2.37M | 2.53M | 4.96M | — | — | — | — | — | — | 100,000 | — | — | — | -300,000 |
| Financing Cash Flow | -14.99M | -41.09M | -181.41M | -119.44M | -157.05M | -105.28M | -53.82M | -138.56M | -49.16M | -153.99M | -10.62M | -66.70M | -33.41M | -28.58M | -29.63M | -29.77M | -73.90M | -32.45M | -46.24M | -33.52M | -4.73M | -6.72M | -33,000 | -2.92M | -23.30M | 1.10M | 200,000 | 200,000 | 2.20M |
| Other Cash Details | |||||||||||||||||||||||||||||
| End Cash Position | 333.25M | 291.32M | 243.65M | 315.94M | 237.69M | 217.23M | 250.54M | 178.95M | 143.21M | 111.13M | 137.34M | 70.84M | 50.35M | 24.22M | 13.66M | 13.28M | 12.87M | 27.03M | 10.58M | 15.07M | 18.97M | 6.69M | 2.47M | 2.90M | 1.40M | 2.60M | — | — | — |
| Income Tax Paid | 44.25M | 45.86M | 59.52M | 53.02M | 54.91M | 70.68M | 46.01M | 52.58M | 35.78M | 26.96M | 26.95M | 27.13M | 24.54M | 21.63M | 22.82M | 19.97M | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Interest Paid | 68,000 | 49,000 | 10,000 | 711,000 | 11,000 | 6,000 | 16,000 | 323,000 | 15,000 | 136,000 | 1,000 | 20,000 | 10,000 | 99,000 | 552,000 | 714,000 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Free Cash Flow | 56.15M | 93.50M | 108.46M | 145.31M | 110.16M | 140.69M | 110.55M | 104.19M | 87.74M | 84.76M | 90.84M | 84.37M | 59.47M | 61.92M | 28.34M | 29.90M | 30.96M | 49.48M | 43.71M | 31.23M | 30.91M | 12.98M | 3.35M | -1.20M | 10.10M | -700,000 | 1.80M | -3.60M | -200,000 |
Error: Invalid format in Holders JSON file.
Article
5 Promising Price-to-Book Value Stocks to Buy in February
The P/B ratio helps to identify low-priced stocks with high growth prospects. GM, USNA, GBX, KT and ENS are some such stocks.
Feb 6, 2025
Article
Kevin Guest Encourages Confidence, Personal Growth for International Boost Self-Esteem Month
SALT LAKE CITY , Feb. 3, 2025 /PRNewswire/ -- Throughout February, Kevin Guest invites individuals everywhere to celebrate International Boost Self-Esteem Month—a time dedicated to building confidence, fostering self-worth and inspiring personal empowerment. Because self-esteem is the cornerstone of a healthy, fulfilling life—shaping relationships, fueling careers and influencing overall well-being—now is the ideal time for individuals to prioritize themselves and take meaningful steps toward becoming more confident and empowered.
Feb 3, 2025
Article
USNA vs. STVN: Which Stock Is the Better Value Option?
Investors looking for stocks in the Medical - Drugs sector might want to consider either USANA Health Sciences (USNA) or Stevanato Group (STVN). But which of these two stocks offers value investors a better bang for their buck right now?
Jan 29, 2025
